Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

KIR3DL1/ HL A-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.

Boudreau JE, Giglio F, Gooley TA, Stevenson PA, Le Luduec JB, Shaffer BC, Rajalingam R, Hou L, Hurley CK, Noreen H, Reed EF, Yu N, Vierra-Green C, Haagenson M, Malkki M, Petersdorf EW, Spellman S, Hsu KC.

J Clin Oncol. 2017 Jul 10;35(20):2268-2278. doi: 10.1200/JCO.2016.70.7059. Epub 2017 May 18.

PMID:
28520526
2.

Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications.

Sarvaria A, Jawdat D, Madrigal JA, Saudemont A.

Front Immunol. 2017 Mar 23;8:329. doi: 10.3389/fimmu.2017.00329. eCollection 2017. Review.

3.

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.

Heidenreich S, Kröger N.

Front Immunol. 2017 Feb 8;8:41. doi: 10.3389/fimmu.2017.00041. eCollection 2017. Review.

4.

In celebration of Ruggero Ceppellini: HLA in transplantation.

Petersdorf EW.

HLA. 2017 Feb;89(2):71-76. doi: 10.1111/tan.12955. Review.

PMID:
28102037
5.

Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes.

Hoff GA, Fischer JC, Hsu K, Cooley S, Miller JS, Wang T, Haagenson M, Spellman S, Lee SJ, Uhrberg M, Venstrom JM, Verneris MR.

Biol Blood Marrow Transplant. 2017 Jan;23(1):153-160. doi: 10.1016/j.bbmt.2016.09.028. Epub 2016 Oct 13.

PMID:
27746218
6.

KIR and HLA Genotypes Implicated in Reduced Killer Lymphocytes Immunity Are Associated with Vogt-Koyanagi-Harada Disease.

Levinson RD, Yung M, Meguro A, Ashouri E, Yu F, Mizuki N, Ohno S, Rajalingam R.

PLoS One. 2016 Aug 4;11(8):e0160392. doi: 10.1371/journal.pone.0160392. eCollection 2016.

7.

Diacylglycerol Kinase ζ Is a Target To Enhance NK Cell Function.

Yang E, Singh BK, Paustian AM, Kambayashi T.

J Immunol. 2016 Aug 1;197(3):934-41. doi: 10.4049/jimmunol.1600581. Epub 2016 Jun 24.

8.

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.

Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K.

Blood. 2016 Jul 14;128(2):297-312. doi: 10.1182/blood-2016-03-706317. Epub 2016 May 31.

9.

Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues.

Jaiswal SR, Chakrabarti S.

Adv Hematol. 2016;2016:3467672. doi: 10.1155/2016/3467672. Epub 2016 Mar 24. Review.

10.

Cord Blood as a Source of Natural Killer Cells.

Mehta RS, Shpall EJ, Rezvani K.

Front Med (Lausanne). 2016 Jan 5;2:93. doi: 10.3389/fmed.2015.00093. eCollection 2015. Review.

11.

Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy.

Ruggeri L, Parisi S, Urbani E, Curti A.

Front Immunol. 2015 Oct 15;6:479. doi: 10.3389/fimmu.2015.00479. eCollection 2015. Review.

12.

KIR Genes and Patterns Given by the A Priori Algorithm: Immunity for Haematological Malignancies.

Rodríguez-Escobedo JG, García-Sepúlveda CA, Cuevas-Tello JC.

Comput Math Methods Med. 2015;2015:141363. doi: 10.1155/2015/141363. Epub 2015 Sep 30.

13.

Human Leukocyte Antigen Diversity: A Southern African Perspective.

Tshabalala M, Mellet J, Pepper MS.

J Immunol Res. 2015;2015:746151. doi: 10.1155/2015/746151. Epub 2015 Aug 12. Review.

14.

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.

Lee EM, Yee D, Busfield SJ, McManus JF, Cummings N, Vairo G, Wei A, Ramshaw HS, Powell JA, Lopez AF, Lewis ID, McCall MN, Lock RB.

Haematologica. 2015 Jul;100(7):914-26. doi: 10.3324/haematol.2014.113092.

15.

Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.

Sobecks RM, Wang T, Askar M, Gallagher MM, Haagenson M, Spellman S, Fernandez-Vina M, Malmberg KJ, Müller C, Battiwalla M, Gajewski J, Verneris MR, Ringdén O, Marino S, Davies S, Dehn J, Bornhäuser M, Inamoto Y, Woolfrey A, Shaw P, Pollack M, Weisdorf D, Milller J, Hurley C, Lee SJ, Hsu K.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1589-96. doi: 10.1016/j.bbmt.2015.05.002. Epub 2015 May 8.

16.

Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.

Chen R, Campbell JL, Chen B.

Onco Targets Ther. 2015 Feb 10;8:405-12. doi: 10.2147/OTT.S78567. eCollection 2015. Review.

17.

The impact of HLA and KIR ligand mismatching on unrelated allogeneic hematopoietic stem cell transplantation in Korean adult patients.

Park H, Rho EY, In JW, Kim I, Yoon SS, Park S, Shin S, Park KU, Song EY.

Ann Lab Med. 2015 Jan;35(1):111-7. doi: 10.3343/alm.2015.35.1.111. Epub 2014 Dec 8.

18.

Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.

Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S18-22. doi: 10.1016/j.clml.2014.06.013. Review.

19.

Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.

Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SG, Spellman S, Haagenson MD, Saeturn K, Ladner M, Trachtenberg E, Parham P, Miller JS.

J Immunol. 2014 May 15;192(10):4592-600. doi: 10.4049/jimmunol.1302517. Epub 2014 Apr 18.

20.

HLA variants related to primary sclerosing cholangitis influence rejection after liver transplantation.

Fosby B, Næss S, Hov JR, Traherne J, Boberg KM, Trowsdale J, Foss A, Line PD, Franke A, Melum E, Scott H, Karlsen TH.

World J Gastroenterol. 2014 Apr 14;20(14):3986-4000. doi: 10.3748/wjg.v20.i14.3986.

Supplemental Content

Support Center